Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14556226 | 0.84 | CSNK2A1 (0.38) | NUDT1L3MBTL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22895687 | 0.83 | CCNK (0.36) | NUDT1L3MBTL1GAAKDM4EALDH1A1 | |
| SCHEMBL22911916 | 0.80 | NUDT1 (0.59) | NUDT1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL2966721 | 0.80 | CDK1 (0.42) | L3MBTL1GAAPDE4DKDM4EALDH1A1 | |
| SCHEMBL15585227 | 0.80 | KDM4E (0.33) | L3MBTL1GAAPDE4DKDM4EALDH1A1 | |
| SCHEMBL6983132 | 0.80 | POLB (0.46) | L3MBTL1GAAPDE4DKDM4EALDH1A1 | |
| SCHEMBL22895389 | 0.79 | TSHR (0.41) | NUDT1L3MBTL1GAAKDM4EALDH1A1 | |
| SCHEMBL1981633 | 0.78 | ALDH1A1 (0.46) | NUDT1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22895410 | 0.76 | NUDT1 (0.41) | NUDT1ALDH1A1PIN1STK17BSTK17A | |
| SCHEMBL5723588 | 0.76 | PIN1 (0.56) | L3MBTL1GAAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2022-12-08 | — | — | US | disclosed |
| US-11390618-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| EP-3999498-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114401955-A | Inhibitors of cyclin dependent kinases | 金耐特生物制药公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3813819-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358958-B2 | — | CDK2, CDK1, CDK6 | NUDT1 1346/4885L3MBTL1 3067/4885GAA 1132/4885 |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | NUDT1 1507/4885L3MBTL1 3049/4885GAA 1676/4885 |
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | NUDT1 1515/4885L3MBTL1 2962/4885GAA 1638/4885 |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, PKN2 | NUDT1 37/4885L3MBTL1 468/4885GAA 1741/4885 |
| US-11390618-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | NUDT1 1507/4885L3MBTL1 3049/4885GAA 1676/4885 |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | NUDT1 1496/4885L3MBTL1 940/4885GAA 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.